Erythropoietin stimulating agents in the management of anemia of chronic kidney disease
- PMID: 19920963
- PMCID: PMC2769266
- DOI: 10.2147/ppa.s2356
Erythropoietin stimulating agents in the management of anemia of chronic kidney disease
Abstract
Anemia is a very common clinical problem in patients with chronic kidney disease (CKD) and is associated with increased morbidity and mortality in these patients. Erythropoietin is a hormone synthesized in the kidney responsible for red blood cell maturation in the bone marrow. It is deficient in the majority of patients with advanced kidney disease thereby predisposing to anemia. Since the approval of recombinant human erythropoietin (epoetin alfa) by the US FDA in 1989, epoetin alfa and similar agents now collectively known as erythropoietin stimulating agents (ESA) have become the standard of care for the treatment of the erythropoietin-deficient anemia that occurs in most patients with CKD. In this review, we have outlined the considerations that need to be taken into account when prescribing ESA for the treatment of anemia in CKD.
Keywords: anemia; chronic kidney disease; erythropoietin stimulating agents.
Similar articles
-
Time spent on erythropoietin stimulating agents administration in hemodialysis centers in Panama: a time and motion study.J Med Econ. 2019 Aug;22(8):736-741. doi: 10.1080/13696998.2019.1600527. Epub 2019 Apr 12. J Med Econ. 2019. PMID: 30915883
-
Trends in anemia care in non-dialysis-dependent chronic kidney disease (CKD) patients in the United States (2006-2015).BMC Nephrol. 2018 Nov 9;19(1):318. doi: 10.1186/s12882-018-1119-7. BMC Nephrol. 2018. PMID: 30413150 Free PMC article.
-
Epoetin alfa and darbepoetin alfa: effects on ventricular hypertrophy in patients with chronic kidney disease.J Nephrol. 2008 Jul-Aug;21(4):543-9. J Nephrol. 2008. PMID: 18651544 Clinical Trial.
-
Meeting new challenges in the management of anemia of chronic kidney disease through collaborative care with pharmacists.Ann Pharmacother. 2009 Nov;43(11):1857-66. doi: 10.1345/aph.1M035. Epub 2009 Oct 13. Ann Pharmacother. 2009. PMID: 19826095 Review.
-
Use of erythropoietin-stimulating agents in breast cancer patients: a risk review.Am J Health Syst Pharm. 2009 Jul 1;66(13):1180-5. doi: 10.2146/ajhp080214. Am J Health Syst Pharm. 2009. PMID: 19535656 Review.
Cited by
-
A Mechanism-Based Population Pharmacokinetics Model of Erythropoietin in Premature Infants and Healthy Adults Following Multiple Intravenous Doses.J Clin Pharmacol. 2019 Jun;59(6):835-846. doi: 10.1002/jcph.1368. Epub 2019 Jan 7. J Clin Pharmacol. 2019. PMID: 30618050 Free PMC article.
-
Cost-effectiveness analysis of intravenous ferumoxytol for the treatment of iron deficiency anemia in adult patients with non-dialysis-dependent chronic kidney disease in the USA.Clinicoecon Outcomes Res. 2017 Sep 20;9:557-567. doi: 10.2147/CEOR.S139950. eCollection 2017. Clinicoecon Outcomes Res. 2017. PMID: 29033594 Free PMC article.
-
Effectiveness of Lactoferrin in the Treatment of Anemia in Chronic Kidney Disease: A Single-Center Pilot Study.Indian J Nephrol. 2024 May-Jun;34(3):222-227. doi: 10.4103/ijn.ijn_13_23. Epub 2023 Oct 23. Indian J Nephrol. 2024. PMID: 39114392 Free PMC article.
-
Prolyl hydroxylase inhibitor desidustat improves anemia in erythropoietin hyporesponsive state.Curr Res Pharmacol Drug Discov. 2022 Apr 30;3:100102. doi: 10.1016/j.crphar.2022.100102. eCollection 2022. Curr Res Pharmacol Drug Discov. 2022. PMID: 35570856 Free PMC article.
-
Three unrelated protease inhibitors enhance accumulation of pharmaceutical recombinant proteins in Nicotiana benthamiana.Plant Biotechnol J. 2018 Oct;16(10):1797-1810. doi: 10.1111/pbi.12916. Epub 2018 May 24. Plant Biotechnol J. 2018. PMID: 29509983 Free PMC article.
References
-
- Barany H-J, Muller Maintaining control over haemoglobin levels: optimizing the management of anaemia in chronic kidney disease. Nephrol Dial Transplant. 2007;22(Suppl 4):iv10–iv18. - PubMed
-
- Brugnara C. Iron deficiency and erythropoiesis: new diagnostic approaches. Clin Chem. 2003;49:1573–8. - PubMed
-
- Collins AJ, Ma JZ, Ebben J. Impact of hematocrit on morbidity and mortality. Semin Nephrol. 2000;20:345. - PubMed
-
- Coyne DW, Kapoian T, Suki W, et al. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: Results of the dialysis patients’ response to IV iron with elevated ferritin (DRIVE) study. J Am Soc Nephrol. 2007;18:975. - PubMed
-
- Drueke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med. 2006;355:2071–84. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources